Grant & Eisenhofer has been appointed as lead counsel in a consolidated class action lawsuit against CIBC and RBC, alleging illegal stock market manipulation of Quantum BioPharma shares. The lawsuit involves claims of market manipulation between 2020 and 2024.
Why it matters. Quantum BioPharma and its shareholders may seek significant damages, affecting the financial standing of the banks involved.
According to Grant & Eisenhofer, the firm has recovered over USD $30 Billion dollars for its clients to date
Quantum retains ownership of 19.48% (as of June 30, 2026) of Unbuzzd.
Once $250 million is reached, the royalty drops to 3% in perpetuity.
The agreement with Unbuzzd also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum total $250 million.
Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. ("Lucid"), Quantum is focused on the research and development of its lead compound, Lucid-MS.
08, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that the United States District Court…
The Quantum Biopharma lawsuit alleged that between January 1, 2020, and August 15, 2024, the Defendants and/or their customers used “spoofing” techniques to manipulate the share price of Quantum BioPharma shares. The class action lawsuit filed December 11, 2025, alleges that bet…
